the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Official Title A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Principal Investigator Larson, Richard
Brief Summary The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs with BCR-ABL ratios ≥ 1% IS at screening.
Gender All
Ages 18 Years
Enrollment 222
Accepts Healthy Volunteers No
Lead Sponsor Novartis PharmaceuticalsIndustry
Study Design
Study Phase Phase 3
Study Type Interventional
Contact Name David S Snyder
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Chronic Myelogenous Leukemia
Detail for Health Professional (on
More clinical trials by this PI